Holen Sie sich die Stockscreener-App
10.94
7.68%
0.78
Vorhandelsmarkt:
11.03
0.09
+0.82%
Cullinan Therapeutics Inc Aktie (CGEM) Neueste Nachrichten
Cullinan Therapeutics (NASDAQ:CGEM) Shares Up 9.5%Here's Why - MarketBeat
Cullinan Therapeutics, Inc.Common Stock (NQ:CGEM) - FinancialContent
Oncology Drugs Fast-Tracked by the FDA in December 2025 - Oncology News Central
Cullinan Therapeutics (NASDAQ:CGEM) Trading Up 3.9%What's Next? - MarketBeat
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Cullinan Therapeutics, Inc. (NASDAQ:CGEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Nadim Ahmed Sells 9,922 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Assenagon Asset Management S.A. Has $1.05 Million Stake in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Cullinan Therapeutics (CGEM) price target increased by 19.75% to 32.84 - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap DownTime to Sell? - MarketBeat
Insider Sell: Jennifer Michaelson Sells Shares of Cullinan Thera - GuruFocus
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $13,463.45 in Stock - MarketBeat
Cullinan Therapeutics CSO Sells Shares - TradingView — Track All Markets
Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells $28,023.66 in Stock - Defense World
Cullinan Therapeutics (CGEM) Price Target Increased by 19.75% to 32.84 - Nasdaq
Will Cullinan Therapeutics Inc. stock deliver shareholder value2025 Price Targets & Weekly High Potential Stock Alerts - ulpravda.ru
Cullinan Therapeutics price target raised to $34 from $25 at Wedbush - MSN
Cullinan Therapeutics Earnings Notes - Trefis
Cullinan Therapeutics shows rising price performance with jump to 93 RS rating - MSN
Is Cullinan Therapeutics Inc. stock a contrarian buy2025 Fundamental Recap & Free Real-Time Market Sentiment Alerts - Улправда
Jacquelyn Sumer Sells 3,480 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Jeffrey Alan Jones Sells 4,632 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Cullinan Therapeutics Executives Sell Shares for Tax Obligations - TradingView — Track All Markets
Officer Michaelson Files To Sell 1,345 Of Cullinan Therapeutics Inc [CGEM] - TradingView — Track All Markets
How Cullinan Therapeutics Inc. stock reacts to inflationary pressures2025 Sector Review & Reliable Intraday Trade Plans - Улправда
Jobs Data: Will Cullinan Therapeutics Inc. stock deliver better than expected guidanceMarket Trend Summary & Technical Buy Zone Confirmations - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Cullinan Management (CGEM) - The Globe and Mail
Will Cullinan Therapeutics (NASDAQ:CGEM) Spend Its Cash Wisely? - Yahoo Finance
Cowen reiterates Buy rating on Cullinan Oncology stock after ASH data - Investing.com Nigeria
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 2,148 Shares of Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Insider Jennifer Michaelson Sells 995 Shares - MarketBeat
Cullinan Therapeutics (CGEM) Jumps on Promising Phase 1 Data for CLN-049 in AML, Showing Strong Response Rates - Finviz
Cullinan Therapeutics presents promising CLN-049 data - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 9.5%What's Next? - MarketBeat
20 Stocks That Will Double in 2026 - Insider Monkey
Cullinan Therapeutics, Inc. (CGEM) Presents at The 67th American Society of Hematology (ASH) Annual MeetingSlideshow (NASDAQ:CGEM) 2025-12-11 - Seeking Alpha
Weekly Research Analysts’ Ratings Updates for Cullinan Therapeutics (CGEM) - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $34.00 at Wedbush - Defense World
Wedbush Maintains Cullinan Therapeutics (CGEM) Outperform Recommendation - Nasdaq
Holdings of Cullinan Therapeutics Inc (CGEM) are aligned with the stars - setenews.com
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $34.00 - MarketBeat
Wedbush Raises Price Target on CGEM to $34, Maintains Outperform - GuruFocus
CGEM: CLN-049 demonstrates strong efficacy and safety in AML, advancing toward pivotal trials - TradingView — Track All Markets
Cullinan Therapeutics (NASDAQ:CGEM) Trading 9.3% HigherWhat's Next? - MarketBeat
Cullinan Oncology stock soars after promising AML treatment results By Investing.com - Investing.com Canada
Cullinan’s leukemia drug shows promising results in clinical trial By Investing.com - Investing.com South Africa
Cullinan Therapeutics Presents Promising CLN-049 Data - TipRanks
Cullinan Therapeutics (CGEM) Reveals Encouraging Phase 1 Data fo - GuruFocus
Cullinan’s leukemia drug shows promising results in clinical trial - Investing.com
Cullinan Therapeutics Reports Promising Phase 1 Data for CLN-049 in Patients with Relapsed/Refractory AML, Receives FDA Fast Track Designation - Quiver Quantitative
Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting - GlobeNewswire
28.63%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):